Cough relief for pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new extended-release medicine, nalbuphine, to reduce chronic coughing in people with idiopathic pulmonary fibrosis (a lung disease that scars the lungs). It may help make cough less frequent and less bothersome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring.
- You have had a chronic cough for at least 8 weeks before starting the study.
- Your cough is at least moderately severe, as self-assessed on a rating scale.
- Your lung function tests show FVC (a measure of how much air you can breathe out) is at least 40% of predicted, and DLCO (a measure of oxygen transfer) is at least 25% of predicted.
- If you take antifibrotic medicines (like nintedanib, pirfenidone, or nerandomilast), you must be on a stable dose for at least 6 weeks before the study starts.
- You have not had a recent respiratory infection or hospitalization for breathing problems in the past 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an extended-release tablet called nalbuphine to reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring and often leads to a persistent cough. If you have IPF and have been coughing for at least 8 weeks, this study may help manage that symptom.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This study tests an inhaled medication for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if the drug is safe and how it works in the body. It might help by targeting the lungs directly with fewer side effects.
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This trial tests whether an extended-release medication called nalbuphine can reduce coughing in people with chronic cough that hasn't improved with other treatments. You may be eligible if you've had a persistent cough for at least a year and have already tried treatments for conditions that could cause it.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.